Commentary

Important Lessons from ONTARGET

Important Lessons from ONTARGET

In the past year, an important landmark study demonstrated therapeutic equivalence of the ACE inhibitor ramipril and the angiotensin receptor blocker (ARB) telmisartan in reducing the risk of all forms of atherosclerotic events.

Urine Test Detects Upper Tract TCC

With upper tract transitional cell carcinoma (UTTCC), vigilance is the watchword. Detecting this cancer earlier may directly impact patient survival. According to the American Cancer Society, 54,390 new cases and 14,100 deaths in the United States will occur during 2008.

In Clinical Trials, Does One Size Fit All?

Practicing evidence-based medicine can be difficult in nephrology, where randomized controlled trials are few and far between. In general, the more that trials use hard outcomes such as morbidity and mortality, the greater our confidence that the therapies will have an impact on patients’ lives. Using end points such as these, however, often require large sample sizes.

Next post in Commentary